(HealthDay)—A new risk prediction score outperforms current guidelines for predicting venous thromboembolism (VTE) in multiple myeloma (MM), according to a study published online Aug. 4 in the American Journal of Hematology.
Aug 7, 2019
0
3
(HealthDay)—Octogenarians with acute myeloid leukemia (AML) have a one-month mortality rate of 41 percent and overall survival (OS) of 1.5 months, according to a research letter published in the June issue of the American ...
May 21, 2019
0
1
New research led by Cancer Council Queensland and Curtin University has investigated the patterns and trends of a rare group of blood cancers known as myeloproliferative neoplasms (MPN) for the first time in Australia.
Mar 22, 2019
0
0
Sickle Cell Disease (SCD) is rare but devastating. Due to a genetic mutation affecting hemoglobin, the component of the red blood cell that carries oxygen, a reduced amount of oxygen is supplied to vital tissues and organs. ...
Feb 6, 2019
0
18
In a study tracking the severe crisis pain of sickle cell disease and its management in 73 adults over a period of a year, Johns Hopkins researchers found that even among those on high doses of daily at-home opioids, a persistent ...
Nov 27, 2018
0
19
Researchers at Mayo Clinic have developed a new genetics-based prognostic tool for myelodysplastic syndrome. Their findings are published in the October print issue of Mayo Clinic Proceedings.
Oct 1, 2018
0
48
(HealthDay)—Fostamatinib produces clinically meaningful responses in adults with immune thrombocytopenia (ITP), according a study published in the July issue of the American Journal of Hematology.
Sep 5, 2018
0
0
(HealthDay)—Rituximab treatment seems effective for systemic lupus erythematosus (SLE)-associated immune cytopenias, with an overall initial response rate of 86 percent, according to a study published online Dec. 16 in ...
Dec 27, 2017
0
6
(HealthDay)—For heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM), bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide (VDT PACE) regimen and its modifications ...
Dec 7, 2017
0
3
St. Jude Children's Research Hospital investigators have shown that using the drug hydroxyurea to boost average fetal hemoglobin levels above 20 percent in children and teenagers with sickle cell anemia was associated with ...
Nov 9, 2017
0
0
